939
We report five cases of carboplatin (CBDCA) hypersensitivity after weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy in patients with recurrent ovarian cancer receiving multiple platinum-based chemotherapy.
 patients with recurrent ovarian cancer: Subject; five: Subject.Population; carboplatin (CBDCA) hypersensitivity: Effect; weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy: Treatment; multiple platinum-based chemotherapy: Treatment; paclitaxel: Treatment.Drug; m2)/CBDCA: Treatment.Drug; carboplatin: Treatment.Drug; platinum: Treatment.Drug; low-dose: Treatment.Dosage; 60 mg/m2)/CBDCA: Treatment.Dosage; weekly: Treatment.Freq; recurrent ovarian cancer: Treatment.Disorder; chemotherapy: Treatment.Route; paclitaxel: Combination.Drug; m2)/CBDCA: Combination.Drug; platinum: Combination.Drug
Given event type and trigger, please tell me the arguments of all the listed option. Output format is "name1: role1; name2: role2". 
Event type: adverse event 
  Option: Treatment.Freq, Subject.Population, Combination.Drug, Subject.Gender, Treatment.Duration, Subject, Effect, Treatment, Treatment.Disorder, Subject.Disorder, Treatment.Route, Subject.Race, Treatment.Time_elapsed, Treatment.Dosage, Subject.Age, Treatment.Drug 
Text: {0} 
Answer:
 patients with recurrent ovarian cancer: Subject; five: Subject.Population; carboplatin (CBDCA) hypersensitivity: Effect; weekly low-dose paclitaxel (60 mg/m2)/CBDCA (area under the concentration curve = 2) therapy: Treatment; multiple platinum-based chemotherapy: Treatment; paclitaxel: Treatment.Drug; m2)/CBDCA: Treatment.Drug; carboplatin: Treatment.Drug; platinum: Treatment.Drug; low-dose: Treatment.Dosage; 60 mg/m2)/CBDCA: Treatment.Dosage; weekly: Treatment.Freq; recurrent ovarian cancer: Treatment.Disorder; chemotherapy: Treatment.Route; paclitaxel: Combination.Drug; m2)/CBDCA: Combination.Drug; platinum: Combination.Drug